Theracos

Privately held: no public share price · China / United States

Assets

(1 total)
1Total Assets
1Approved
0Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Bexagliflozin(Brenzavvy)
Approved
SGLT2Small molecule
Type 2 Diabetes

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

1 April 2024Topline resultTHR-1442Phase 3 NCT05159882 published: bexagliflozin (THR-1442) noninferior to dapagliflozin on HbA1c at week 24
CN · Newsoara Biopharma Co., Ltd. (with TheracosBio authors) · Source ↗

Financial reports

No financial reports recorded.